U.S. markets close in 2 hours 58 minutes

CareDx, Inc (CDNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
73.12+1.68 (+2.35%)
As of 1:02PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close71.44
Open72.53
Bid72.97 x 1300
Ask73.16 x 800
Day's Range72.53 - 74.98
52 Week Range21.33 - 99.83
Volume189,212
Avg. Volume807,504
Market Cap3.789B
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateFeb 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est98.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CareDx Announces New HLA Typing Service Offering for Research Purposes
    GlobeNewswire

    CareDx Announces New HLA Typing Service Offering for Research Purposes

    Initial projects underway for global pharmaceutical companySOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that they have launched a fully-functional next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies. The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time. AlloSeq Tx17 provides over 50% more gene content than other NGS solutions on the market, including 11 classical HLA loci as well as HLA-E, -F, -G, -H, MICA, and MICB. CareDx’s HLA typing service in Stockholm has been engaged by one of the top 10 global pharmaceutical companies in the world, providing initial testing results in the first quarter of 2021. “This is an exciting time for CareDx – we are not only expanding our capabilities but also investing in our global team to provide a first ever CareDx testing service outside the United States,” said Alexander Johnson, SVP, Products, Cell Therapy and Business Development, CareDx. “This expansion allows us to partner with those at the forefront of drug development research and support improved care for even more patients around the world.” For more information on HLA typing services in Europe, please contact hlatypingservice@caredx.com About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com

  • CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings
    GlobeNewswire

    CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings

    CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education ProgramSOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021. As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Care for Kidney Transplant Patients,” a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time. Program details: Innovations in Kidney Transplant Care, with Dr. Christopher Boshkos, Medical Director of Kidney Transplantation at CareDxAlloSure: Standard of Care for Kidney Transplant Surveillance, with Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine “I’m looking forward to highlighting research from the RADAR study, where AlloSure differentiates ambiguous allograft rejection in borderline cases, and presenting select case studies to illustrate long-term patient follow up with AlloSure from the KOAR registry,” said Dr. Matthew Weir, Division Head of Nephrology at the University of Maryland School of Medicine. In addition, CareDx is sponsoring the “Diagnosis of Acute Rejection in Kidney Transplantation: A Clinical Update,” a continuing medical education (CME) program on April 8th from 12:30–1:30 p.m. Eastern Time. Program details: Acute Rejection in Kidney Transplantation: Pathophysiology and Impact on Outcomes, presented by Tarek Alhamad, MD, MS, Medical Director of Transplant Nephrology at Washington University School of Medicine in St. Louis Diagnostic Modalities for Acute Rejection in Kidney, presented by Deirdre Sawinski, MD, Assistant Medical Director, Penn Kidney Pancreas Transplant Program Advances in Non-Invasive Diagnosis of Acute Rejection in Kidney Transplantation, presented by Jonathan Bromberg, MD, PhD, Vice Chair for Research, University of Maryland School of Medicine “The NKF Spring Clinical Meetings are always a highlight for us,” said Dr. Sham Dholakia, SVP Medical Affairs, CareDx. “We are excited to showcase the latest in kidney transplant surveillance data at this great event.” Additional information is available at https://www.kidney.org/spring-clinical About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com

  • 3 Cancer Diagnostic Monster Stocks on Sale
    Motley Fool

    3 Cancer Diagnostic Monster Stocks on Sale

    These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.